References
- Steiner TJ, Stovner LJ, Birbeck GL. Migraine: the seventh disabler. J Headache Pain. 2013;14:1.
- Munakata J, Hazard E, Serrano D, et al. Economic burden of transformed migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study. Headache. 2009;49(4):498–508.
- Smitherman TA, Burch R, Sheikh H, et al.. The prevalence, impact, and treatment of migraine and severe headaches in the United States: a review of statistics from national surveillance studies. Headache. 2013;53(3):427–436.
- Rogawski MA. Common Pathophysiologic mechanisms in migraine and epilepsy. Arch Neurol. 2008;65(6):709–714.
- Pietrobon D, Striessnig J. Neurobiology of migraine. Nat Rev Neurosci. 2003;4(5):386–398.
- Tajti J, Szok D, Csáti A, et al.. Prophylactic drug treatment of migraine in children and adolescents: an update. Curr Pain Headache Rep. 2016;20(1):1.
- Syed YY. Sumatriptan/Naproxen Sodium: a review in migraine. Drugs. 2016;76(1):111–121.
- McKeage K. Zolmitriptan Nasal Spray: a review in acute migraine in pediatric patients 12 years of age or older. Paediatr Drugs. 2016;18(1):75–81.
- Patniyot IR, Gelfand AA. Acute treatment therapies for pediatric migraine: a qualitative systematic review. Headache. 2016;56(1):49–70.
- Irimia P, Palma J, Torron RF, et al.. Refractory migraine in a headache clinic population. BMC Neurol. 2011;11:94.
- Hatef B, Hashemirad F, Meftahi GH, et al.. The efficiency of pulsed electromagnetic field in refractory migraine headaches: a randomized, single-blinded, placebo-controlled, parallel group. Int J Clin Trials. 2016;3(1):24–31.
- Gelfand AA, Goadsby PJ. A Neurologist’s guide to acute migraine therapy in the emergency room. Neurohospitalist. 2012;2(2):51–59.
- Woldeamanuel YW, Rapoport AM, Cowan RP. What is the evidence for the use of corticosteroids in migraine? Curr Pain Headache Rep. 2014;18(12):464.
- Krusz J, Cagle J, Scott-Krusz V. IV ketamine treatment for multiple headache and pain disorders. ANODYNE Headache PainCare (Dallas, TX). 2010;11(4):S43.
- Mohseni M, Fatehi F. Propofol alleviates intractable migraine headache: A case report. Anesthesiol Pain Med. 2012;2(2):94–96.
- Baker MT. The anticonvulsant effects of propofol and a propofol analog, 2,6-diisopropyl-4-(1-hydroxy-2,2,2-trifluoroethyl)phenol, in a 6 Hz partial seizure model. Anesth Analg. 2011;112(2):340–344.
- Soleimanpour H, Ghafouri RR, Taheraghdam A, et al. Effectiveness of intravenous dexamethasone versus propofol for pain relief in the migraine headache: a prospective double blind randomized clinical trial. BMC Neurol. 2012; 12:114.
- Hippalgaonkar K, Majumdar S, Kansara V. Injectable lipid emulsions—advancements, opportunities and challenges. AAPS Pharm Sci Tech. 2010;11(4):1526–1540.
- Nandiwale KY, Bokade VV. Selective synthesis of propofol (2,6-diisopropylphenol), an intravenous anesthetic drug, by isopropylation of phenol over H-beta and H-mordenite. RSC Adv. 2014;4:32467–32474.
- Baker MT, Propofol: NM. The challenges of formulation. Anesthesiology. 2005;103(4):860–876.
- Kanto J, Gepts E. Pharmacokinetic implications for the clinical use of propofol. Clin Pharmacokinet. 1989;17(5):308–326.
- Shafer A, Doze VA, Shafer SL, et al.. Pharmacokinetics and pharmacodynamics of propofol infusions during general anesthesia. Anesthesiology. 1988;69(3):348–356.
- Reinsel RA, Veselis RA, Wronski M, et al.. The P300 event-related potential during propofol sedation: a possible marker for amnesia? Br J Anaesth. 1995;74:674–680.
- Samra SK, Sneyd JR, Ross DA, et al.. Effects of propofol sedation on seizures and intracranially recorded epileptiform activity in patients with partial epilepsy. Anesthesiology. 1995;82(4):843–851.
- Thompson KA, Goodale DB. The recent development of propofol (DIPRIVAN). Intensive Care Med. 2000;26(4):S400–S404.
- Udelsmann A, Saccomani P, Dreyer E, et al.. Treatment of status migrainosus by general anesthesia: a case report. Braz J Anesthesiol. 2015;65(5):407–410.
- Irifune M, Takarada T, Shimizu Y, et al. Propofol-induced anesthesia in mice is mediated by gamma-aminobutyric acid-A and excitatory amino acid receptors. Anesth Analg. 2003;97(2):424–429.
- Takei T, Saegusa H, Zong S, et al.. Increased sensitivity to halothane but decreased sensitivity to propofol in mice lacking the N-type Ca2+ channel. Neurosci Lett. 2003;350(1):41–45.
- Nicolodi M, Sicuteri F. Exploration of NMDA receptors in migraine: therapeutic and theoretic implications. Int J Clin Pharmacol Res. 1995; 15(5–6):181–189.
- Noruzzadeh R, Modabbernia A, Aghamollaii V, et al. Memantine for prophylactic treatment of migraine without aura: A randomized double-blind placebo-controlled study. Headache. 2016;56(1):95–103.
- Strong AJ, Fabricius M, Boutelle MG, et al. Spreading and synchronous depressions of cortical activity in acutely injured human brain. Stroke. 2002;33(12):2738–2743.
- Kudo C, Toyama M, Boku A, et al. Anesthetic effects on susceptibility to cortical spreading depression. Neuropharmacology. 2013;67:32–36.
- Bogdanov VB, Multon S, Chauvel V, et al. Migraine preventive drugs differentially affect cortical spreading depression in rat. Neurobiol Dis. 2011;41(2):430–435.
- Ayata C, Jin H, Kudo C, et al.. Suppression of cortical spreading depression in migraine prophylaxis. Ann Neurol. 2006;59(4):652–661.
- Hertle DN, Dreier JP, Woitzik J, et al. Effect of analgesics and sedatives on the occurrence of spreading depolarizations accompanying acute brain injury. Brain. 2012;135(8):2390–2398.
- Sakowitz OW, Kiening KL, Krajewski KL, et al. Preliminary evidence that ketamine inhibits spreading depolarizations in acute human brain injury. Stroke. 2009;40(8):e519–e522.
- Dhir A, Lossin C, Rogawski MA. Propofol hemisuccinate suppresses cortical spreading depression. Neurosci Lett. 2012;514(1):67–70.
- Takagaki M, Feuerstein D, Kumagai T, et al.. Isoflurane suppresses cortical spreading depolarizations compared to propofol–implications for sedation of neurocritical care patients. Exp Neurol. 2014;252:12–17.
- Krusz JC, Scott V, Belanger J. Intravenous propofol: unique effectiveness in treating intractable migraine. Headache. 2000;40(3):224–230.
- Moshtaghion H, Heiranizadeh N, Rahimdel A, et al.. The efficacy of propofol vs. subcutaneous sumatriptan for treatment of acute migraine headaches in the emergency department: a double-blinded clinical trial. Pain Pract. 2015;15(8):701–705.
- Sheridan DC, Spiro DM, Nguyen T, et al.. Low-dose propofol for the abortive treatment of pediatric migraine in the emergency department. Pediatr Emerg Care. 2012;28(12):1293–1296.
- Sato K, Hida A, Arai N, et al.. Low-dose intravenous propofol as a possible therapeutic option for acute confusional migraine. Am J Emerg Med. 2016 [cited 2016 Jul 2]. doi:10.1016/j.ajem.2016.06.104.
- Earley PH, Finver T. Addiction to propofol: a study of 22 treatment cases. J Addict Med. 2013;7(3):169–176.